drugset / Trial / NCT00135083

Variable Bolus Regimen 1-2-3 for Type 2 Diabetes Mellitus

NCT00135083

Phase 3 Completed 347 enrolled Sanofi
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to show the non-inferiority of insulin glulisine administered with 1 meal versus 2 meals versus 3 daily meals, as measured by the change in hemoglobin A1c (HbA1c), from baseline to study week 24.

Timeline

Start
2004-08
Primary completion
Completion
2007-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin glulisine Protein / enzyme biologic 10 iu